Eli Lilly moved to expand its gene‑therapy footprint by acquiring Adverum in a deal that transfers Adverum’s ocular gene‑therapy programs into Lilly’s portfolio. The transaction marks a notable buy at a time when several large pharma firms are re-evaluating gene and cell therapy investments. Lilly said the acquisition strengthens its capability in ocular indications and complements its broader biologics and rare‑disease strategy. The deal underscores continued consolidation as big pharmas selectively double down on gene therapy assets despite a challenging commercial backdrop.